Moderna (MRNA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Moderna (MRNA) reported $1.86 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 1.7%. EPS of $0.03 for the same period compares to -$1.39 a year ago.The reported revenue represents a surprise of +47.73% over the Zacks Consensus Estimate of $1.26 billion. With the consensus EPS estimate being -$1.89, the EPS surprise was +101.59%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Moderna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product sales- Rest of world: $324 million compared to the $362.69 million average estimate based on two analysts. The reported number represents a change of -56.3% year over year. Product sales- United States: $1.22 billion versus the two-analyst average estimate of $728.42 million. The reported number represents a year-over-year change of +33.1%. Revenue- Net Product sales: $1.82 billion versus the eight-analyst average estimate of $1.22 billion. The reported number represents a year-over-year change of +3.6%. Revenue- Other revenue: $42 million versus $16.30 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -43.2% change. Revenue- Other revenue- Grant revenue: $7 million versus $8.75 million estimated by two analysts on average. View all Key Company Metrics for Moderna here>>>Shares of Moderna have returned -11.5% over the past month versus the Zacks S&P 500 composite's +4.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Free: 5 Stocks to Buy As Infrastructure Spending SoarsTrillions of dollars in Federal funds have been earmarked to repair and upgrade America’s infrastructure. In addition to roads and bridges, this flood of cash will pour into AI data centers, renewable energy sources and more.In, you’ll discover 5 surprising stocks positioned to profit the most from the spending spree that’s just getting started in this space.Download How to Profit from the Trillion-Dollar Infrastructure Boom absolutely free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Moderna, Inc. (MRNA): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks